Research ExplorerPublicationsA Versatile Microarray Platform for Capturing Rare Cells

A Versatile Microarray Platform for Capturing Rare Cells

Standard

A Versatile Microarray Platform for Capturing Rare Cells. / Brinkmann , Falko ; Hirtz, Michael; Haller, Anna; Gorges, Tobias M; Vellekoop, Michael J; Riethdorf, Sabine; Müller, Volkmar; Pantel, Klaus; Fuchs, Harald.

In: SCI REP-UK, Vol. 5, 23.10.2015, p. Art. 15342.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Brinkmann , F, Hirtz, M, Haller, A, Gorges, TM, Vellekoop, MJ, Riethdorf, S, Müller, V, Pantel, K & Fuchs, H 2015, 'A Versatile Microarray Platform for Capturing Rare Cells', SCI REP-UK, vol. 5, pp. Art. 15342. https://doi.org/10.1038/srep15342

APA

Brinkmann , F., Hirtz, M., Haller, A., Gorges, T. M., Vellekoop, M. J., Riethdorf, S., Müller, V., Pantel, K., & Fuchs, H. (2015). A Versatile Microarray Platform for Capturing Rare Cells. SCI REP-UK, 5, Art. 15342. https://doi.org/10.1038/srep15342

Vancouver

Brinkmann F, Hirtz M, Haller A, Gorges TM, Vellekoop MJ, Riethdorf S et al. A Versatile Microarray Platform for Capturing Rare Cells. SCI REP-UK. 2015 Oct 23;5:Art. 15342. https://doi.org/10.1038/srep15342

Bibtex

@article{4d07f1c907254f7d82b2d61eb3551565,
title = "A Versatile Microarray Platform for Capturing Rare Cells",
abstract = "Analyses of rare events occurring at extremely low frequencies in body fluids are still challenging. We established a versatile microarray-based platform able to capture single target cells from large background populations. As use case we chose the challenging application of detecting circulating tumor cells (CTCs) - about one cell in a billion normal blood cells. After incubation with an antibody cocktail, targeted cells are extracted on a microarray in a microfluidic chip. The accessibility of our platform allows for subsequent recovery of targets for further analysis. The microarray facilitates exclusion of false positive capture events by co-localization allowing for detection without fluorescent labelling. Analyzing blood samples from cancer patients with our platform reached and partly outreached gold standard performance, demonstrating feasibility for clinical application. Clinical researchers free choice of antibody cocktail without need for altered chip manufacturing or incubation protocol, allows virtual arbitrary targeting of capture species and therefore wide spread applications in biomedical sciences.",
author = "Falko Brinkmann and Michael Hirtz and Anna Haller and Gorges, {Tobias M} and Vellekoop, {Michael J} and Sabine Riethdorf and Volkmar M{\"u}ller and Klaus Pantel and Harald Fuchs",
year = "2015",
month = oct,
day = "23",
doi = "10.1038/srep15342",
language = "English",
volume = "5",
pages = "Art. 15342",
journal = "SCI REP-UK",
issn = "2045-2322",
publisher = "NATURE PUBLISHING GROUP",

}

RIS

TY - JOUR

T1 - A Versatile Microarray Platform for Capturing Rare Cells

AU - Brinkmann , Falko

AU - Hirtz, Michael

AU - Haller, Anna

AU - Gorges, Tobias M

AU - Vellekoop, Michael J

AU - Riethdorf, Sabine

AU - Müller, Volkmar

AU - Pantel, Klaus

AU - Fuchs, Harald

PY - 2015/10/23

Y1 - 2015/10/23

N2 - Analyses of rare events occurring at extremely low frequencies in body fluids are still challenging. We established a versatile microarray-based platform able to capture single target cells from large background populations. As use case we chose the challenging application of detecting circulating tumor cells (CTCs) - about one cell in a billion normal blood cells. After incubation with an antibody cocktail, targeted cells are extracted on a microarray in a microfluidic chip. The accessibility of our platform allows for subsequent recovery of targets for further analysis. The microarray facilitates exclusion of false positive capture events by co-localization allowing for detection without fluorescent labelling. Analyzing blood samples from cancer patients with our platform reached and partly outreached gold standard performance, demonstrating feasibility for clinical application. Clinical researchers free choice of antibody cocktail without need for altered chip manufacturing or incubation protocol, allows virtual arbitrary targeting of capture species and therefore wide spread applications in biomedical sciences.

AB - Analyses of rare events occurring at extremely low frequencies in body fluids are still challenging. We established a versatile microarray-based platform able to capture single target cells from large background populations. As use case we chose the challenging application of detecting circulating tumor cells (CTCs) - about one cell in a billion normal blood cells. After incubation with an antibody cocktail, targeted cells are extracted on a microarray in a microfluidic chip. The accessibility of our platform allows for subsequent recovery of targets for further analysis. The microarray facilitates exclusion of false positive capture events by co-localization allowing for detection without fluorescent labelling. Analyzing blood samples from cancer patients with our platform reached and partly outreached gold standard performance, demonstrating feasibility for clinical application. Clinical researchers free choice of antibody cocktail without need for altered chip manufacturing or incubation protocol, allows virtual arbitrary targeting of capture species and therefore wide spread applications in biomedical sciences.

U2 - 10.1038/srep15342

DO - 10.1038/srep15342

M3 - SCORING: Journal article

C2 - 26493176

VL - 5

SP - Art. 15342

JO - SCI REP-UK

JF - SCI REP-UK

SN - 2045-2322

ER -